Intellia names Jing L. Marantz chief medical officer

By Public Technologies
  • Intellia Therapeutics named Jing L. Marantz as executive vice president, chief medical officer, effective Oct. 26, 2026.
  • Marantz will lead translational, development, regulatory, medical affairs functions as Intellia prepares for a first in vivo gene-editing commercialization push.
  • She previously served as chief medical officer at Scholar Rock, overseeing development work that supported U.S. approval of ISEMBYLD.
  • Marantz also held senior roles at Krystal Biotech, Acceleron, Alnylam, Alexion, Biogen, ARIAD, Millennium Pharmaceuticals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130730PRIMZONEFULLFEED9843270) on October 13, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk